HARMANCI, A. Et Al. 2013. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. CLINICAL ENDOCRINOLOGY , vol.78, no.1 , 120-125.

HARMANCI, A., Cinar, N., BAYRAKTAR, M., & Yildiz, B. O., (2013). Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. CLINICAL ENDOCRINOLOGY , vol.78, no.1, 120-125.

HARMANCI, AYLA Et Al. "Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome," CLINICAL ENDOCRINOLOGY , vol.78, no.1, 120-125, 2013

HARMANCI, AYLA Et Al. "Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome." CLINICAL ENDOCRINOLOGY , vol.78, no.1, pp.120-125, 2013

HARMANCI, A. Et Al. (2013) . "Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome." CLINICAL ENDOCRINOLOGY , vol.78, no.1, pp.120-125.

@article{article, author={AYLA HARMANCI Et Al. }, title={Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome}, journal={CLINICAL ENDOCRINOLOGY}, year=2013, pages={120-125} }